Monopar TherapeuticsMNPR -1.50%35 PB Ratio is 4.34 as of Jun. 25, 2026. GuruFocus rates MNPR with a GF Score™ of 35/100. The stock has 2 warning signs investors should review. Among 1,233 Biotechnology companies, Monopar Therapeutics ranks worse than 66.83% on this metric.
The historical rank and industry rank for Monopar Therapeutics's PB Ratio or its related term are showing as below:
MNPR'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 4.64
Current: 4.34
During the past 10 years, Monopar Therapeutics's highest PB Ratio was 4.64. The lowest was 0.00. And the median was 0.00.
MNPR's PB Ratio is ranked worse than 66.83% of 1233
companies
in the Biotechnology industry
Industry Median: 2.8
vs MNPR: 4.34
During the past 12 months, Monopar Therapeutics's average Book Value Per Share Growth Rate was 128.40% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 74.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 16.40% per year.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Monopar Therapeutics was 74.20% per year. The lowest was -35.10% per year. And the median was 14.10% per year.
Back to Basics: PB Ratio
Monopar Therapeutics (NAS:MNPR) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Monopar Therapeutics PB Ratio Related Terms
Monopar Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Monopar Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Monopar Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Monopar Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Monopar Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Monopar Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Monopar Therapeutics (MNPR) has a PB Ratio of 4.34 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Monopar Therapeutics and its competitors. According to the industry distribution chart, Monopar Therapeutics ranks #824 out of 1233 companies in the Biotechnology industry, placing it in the top 66.8%.
Is Monopar Therapeutics' PB Ratio too high?
Monopar Therapeutics' current PB Ratio is 4.34. The Biotechnology industry median PB Ratio is 2.80. Monopar Therapeutics' value of 4.34 is 55% above this industry median. Based on the distribution chart, Monopar Therapeutics ranks #824 out of 1233 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Monopar Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Monopar Therapeutics' PB Ratio compare to IPSC and ADCT?
According to the Biotechnology industry distribution chart, Monopar Therapeutics ranks #824 out of 1233 companies for PB Ratio. This places Monopar Therapeutics in the lower half of its industry. The industry median PB Ratio is 2.80. Monopar Therapeutics' value of 4.34 is 55% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Monopar Therapeutics's current PB Ratio of 4.34 is 55% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Monopar Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Monopar Therapeutics's current PB Ratio is 4.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monopar Therapeutics stock overvalued right now?
Monopar Therapeutics (MNPR) has a current PB Ratio of 4.34. The current PB Ratio is 4.34 and 55% above the Biotechnology industry median of 2.80. Monopar Therapeutics' overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Monopar Therapeutics (MNPR), the current PB Ratio is 4.34 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
35GF Score
Get the complete analysis for MNPR
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MNPR has been successfully added to your 
